Vertex, G.D. Searle, Glaxo Wellcome deal

VRTX and partner Glaxo paid $25 million for a non-exclusive, worldwide license to G.D. Searle patent applications in the area of HIV protease inhibition. Glaxo will pay $15 million, while VRTX will pay $10 million. The license enables Glaxo and VRTX to continue development of the protease inhibitor 141W94 ( VX-478) free of intellectual property claims by Searle. VRTX also will pay Searle a royalty on net sales of the product in the U.S. and Europe. Glaxo is conducting a Phase I/II trial of 141W94 in HIV. ...